Do new oral anticoagulants require laboratory monitoring? the clinician point of view

Thrombosis Research

Volumn 130, Issue SUPPL.1, 2012, Pages

  Samama, Meyer Michel ^a,b   Guinet, Céline ^b   Le Flem, Lena ^b  

^a HÔTEL DIEU   (France)

^b Biomnis Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; RIVAROXABAN;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MEASUREMENT; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 84866977076     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.08.286     Document Type: Article

References (15)

1. C.S. Miller, S.M. Grandi, A. Shimony, K.B. Filion, and M.J. Eisenberg Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Am J Cardiol 110 2012 453 460
2. R. De Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Amesen, and F. Bachmann New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on anticoagulants in heart disease position paper J Am Coll Cardiol 59 2012 1413 1425
3. M.M. Samama, and C. Guinet Laboratory assessments of new anti-coagulants Clin Chem Lab Med 49 2011 761 772
4. M. Legrand, J. Mateo, A. Aribaud, S. Ginisty, P. Eftekhari, and P.T. Huy The use of dabigatran in elderly patients Arch Intern Med 171 2011 1285 1286
5. A. Lillo-Lelouet, M. Wolf, L. Soufir, A. Galbois, A.S. Dumenil, and G. Offenstadt Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: Implications for emergency surgery and resuscitation Thromb Haemost 108 2012 3
6. E.L. Cano, and M.A. Miyares Clinical challenges in a patient with dabigatran-induced fatal hemorrhage Am J Geriatr Pharmacother 10 2012 160 163
7. H. Ten Cate Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb Haemost 107 2012 803 805
8. M.R. Boland, M. Murphy, M. Murphy, and E. McDermott Acute-onset severe gastrointestinal tract haemorrhage in a post-operative patient taking Rivaroxaban following total hip arthroplasty: A case report J Med Case Rep 6 2012 129
9. G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement Thromb Res 127 2011 457 465
10. Samama MM, Guinet C, Le Flem L, Ninin E, Debue JM. Measurement of dabigatran in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery. An observational study. J Thromb Thrombolysis in press.
11. M.M. Samama, G. Contant, T. Spiro, E. Perzborn, L. Le Flem, and C. Guinet Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: The results of a multicenter field trial Clin Appl Thromb Hemost 18 2012 150 158
12. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, C. Guinet, and L. Le Flem Evaluation of the anti-Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls Thromb Haemost 107 2012 379 387
13. M.M. Samama, C. Guinet, G. Gerotziafas, and L. Le Flem Influence of dabigatran on coagulation assays, an in-vitro study Poster SSC12-1200 58th Annual Meeting of the SSC of the ISTH, Journal Thromb Haemost 2012 Liverpool
14. A. Tripodi, Y. Chantarangkul, C. Guinet, and M.M. Samama The INR calibrated for Rivaroxaban (INRivaroxaban) has the potential to normalize PT results for rivaroxaban-treated patients. Results of an in vitro study J Thromb Haemost 9 2011 226 228
15. M.M. Samama Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress Presse Med 41 2012 557 559